ARS Pharmaceuticals is dedicated to creating innovative, patient-friendly treatments that address the challenges associated with needle-related risks and the need for portable, easy-to-use medical devices. Their flagship product, neffy, is a groundbreaking needle-free epinephrine nasal spray that has received FDA approval. This product is designed to provide a safe and effective alternative for the emergency treatment of anaphylaxis, a severe allergic reaction. Neffy is specifically formulated to deliver epinephrine in a manner that mimics the pharmacokinetics of traditional injectable forms, ensuring rapid onset and effective symptom resolution. The device's compact size and straightforward "place and press" administration method encourage patients and caregivers to carry and use it promptly when allergic symptoms arise.

The technology behind neffy combines three well-established components: epinephrine, a proven treatment for anaphylaxis; a reliable delivery device with a high success rate; and Intravail®, a proprietary absorption agent that enhances the nasal delivery of the medication. This combination allows neffy to achieve effective dosing while minimizing the risks associated with traditional needle-based delivery systems. ARS Pharmaceuticals emphasizes the importance of education and awareness regarding the use of epinephrine, as many individuals at risk for severe allergic reactions do not carry or use their prescribed treatments effectively. By providing a user-friendly alternative, ARS Pharma aims to improve patient outcomes and reduce the incidence of emergency medical interventions related to anaphylaxis.

United States

Was SilverBack Therapeutics, merged with ARS Pharma in 2023

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including food, medications, and insect bites. The company was founded in 2015 and is based in San Diego, California.

Allergy

ARS Pharmaceuticals

Allergic Reactions (type I)

Anaphylaxis

neffy® (epinephrine nasal spray)

Urticaria

Breast cancer

Cancer

<p class="font_8">TLR8 is highly expressed in myeloid cells that are prevalent in human tumors and TLR8 agonism can potently activate a broad spectrum of anti-tumor immune mechanisms. SBT6050 is designed to activate human myeloid cells in tumors expressing moderate or high levels of HER2. Myeloid cell activation and reprogramming in the tumor microenvironment has emerged as a promising approach to harness the innate immune system to drive anti-tumor responses, including in tumors lacking T cells, as these tumors are often replete with myeloid cells.</p>

ARS Pharmaceuticals

Company Details